SCHEMBL22978447

SCHEMBL22978447

O=C(O)Nc1ccc(C(O)c2c[nH]c3ncccc23)cn1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GRM8 O00222 1/20 0.46
▸ GRM4 Q14833 1/20 0.46
▸ CAMKK2 Q96RR4 2/20 0.40
▸ MAP2K1 Q02750 1/20 0.40
▸ CNR2 P34972 1/20 0.38
▸ KMT2A Q03164 1/20 0.37
▸ AXL P30530 1/20 0.37
▸ ADORA2A P29274 1/20 0.37
▸ BRD4 O60885 1/20 0.37
▸ MET P08581 4/20 0.36
▸ MAPT P10636 1/20 0.36
▸ CDC7 O00311 1/20 0.36
▸ MAP4K4 O95819 1/20 0.36
▸ CDK8 P49336 1/20 0.36
▸ DYRK1A Q13627 1/20 0.36
▸ MELK Q14680 1/20 0.36
▸ MAPK14 Q16539 1/20 0.36
▸ CLK4 Q9HAZ1 1/20 0.36
▸ STK17A Q9UEE5 1/20 0.36
▸ DYRK1B Q9Y463 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22988869 0.84 MAP2K1 (0.40) GRM8GRM4CAMKK2MAP2K1CNR2
SCHEMBL878759 0.80 MET (0.42) GRM8GRM4MAP2K1AXLBRD4
SCHEMBL21872984 0.79 CDC7 (0.41) GRM8GRM4CAMKK2MAP2K1CNR2
SCHEMBL1267952 0.79 AXL (0.48) GRM8GRM4CAMKK2MAP2K1KMT2A
SCHEMBL22978453 0.79 NPC1 (0.35) —
SCHEMBL857039 0.78 MAPT (0.49) GRM8GRM4CAMKK2MAP2K1KMT2A
SCHEMBL1267562 0.78 CDC7 (0.41) GRM8GRM4CNR2BRD4MET
SCHEMBL28467009 0.77 MAP2K1 (0.43) GRM8GRM4CAMKK2MAP2K1CNR2
SCHEMBL1268047 0.76 CSF1R (0.50) METMAPTCDC7MAP4K4DYRK1A
SCHEMBL27975426 0.76 CSF1R (0.48) BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2018233526-A9 CSF1R INHIBITOR, AND MANUFACTURING METHOD THEREFOR AND APPLICATION THEREOF 上海和誉生物医药科技有限公司 2021-02-18 — — WO disclosed
Send feedback